Summary
PROJECT SUMMARY A heart failure diagnosis leads to poor quality of life and a 5-year mortality nearing 50%, underscoring the urgent need for innovative treatments. Clinical evidence strongly links myocardial fibrosis, driven by pathological activation of cardiac fibroblasts, with unfavorable outcomes in heart failure patients. Prior efforts to control fibrosis often targeted signaling pathways, integrins, or extracellular matrix components, affecting many tissues. However, much less is known about the epigenomic mechanisms governing cardiac fibrosis and fibroblast activation. Understanding the
